이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Dizal (Jiangsu) Pharmaceutical 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Zhang Xiaolin

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	1.8%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO

Zhang Xiaolin (60 yo)

no data

테뉴어

CN¥11,727,700

보상

Dr. Zhang Xiaolin Ph.D. is General Manager and Chairman of Dizal (Jiangsu) Pharmaceutical Co., Ltd. and served as its Chief Scientist. Dr. Xiaolin joined the Dizal (Jiangsu) Pharmaceutical Co., Ltd.in 201...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zhang Xiaolin	GM & Chairman	no data	CN¥11.73m	1.76% CN¥ 274.5m
Guanshan Zhu	Independent Director	4yrs	CN¥100.00k	데이터 없음
Simon Dazhong Lu	Director	7.7yrs	데이터 없음	데이터 없음
Rodolphe Peter Andre Grepinet	Director	7.7yrs	데이터 없음	데이터 없음
Jiang Bin	Independent Director	4yrs	CN¥100.00k	데이터 없음
Wang Xuegong	Independent Director	4yrs	CN¥100.00k	데이터 없음
Zhang Xin	Independent Director	4yrs	CN¥100.00k	데이터 없음
Dong Weiwen	Chairman of the Supervisory Board	no data	데이터 없음	데이터 없음
Yuan Sun	Supervisor	no data	데이터 없음	데이터 없음
Xiaojing Kang	Employee Supervisor	2.6yrs	데이터 없음	0.0041% CN¥ 638.2k

4.0yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 688192 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Dizal (Jiangsu) Pharmaceutical 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Less than half of directors are independent

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology

New major risk - Revenue and earnings growth

Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting

Less than half of directors are independent

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령